Advanced intraperitoneal drug solutions for oncology
Long acting therapeutics for the life threatening peritoneal diseases
Peritoneal carcinomatosis
Metastases to the peritoneum
Peritoneal carcinomatosis is a common, but underrated, type of cancer. Common cancers such as colorectal, gastric, and ovarian cancer are notorious for spreading to the peritoneal cavity and cause a substantial number of 1.3 million new cases of peritoneal carcinomatosis each year worldwide.
​
Metastases to the peritoneal cavity have the worst prognosis for patients with little chance of survival over a year and rapid decline of quality of life because current treatment modalities fail to adequately manage peritoneal disease.
​
Current treatment methods rely on traditional products that were developed for intravenous use. Efficacy of such products for the treatment of peritoneal carcinomatosis is hampered by poor drug delivery into the peritoneal cavity and inadequate – too short – duration of drug exposure.
Innovative therapies to treat peritoneal carcinomatosis
Locoregional treatment
of metastasized disease
UPyTher is working to set a new standard of care in peritoneal oncology and make intraperitoneal therapy simple, safe and effective.
UPyTher’s solution is specifically designed for intraperitoneal administration and sustained release of medication in the peritoneal cavity for patients.
UPyTher’s hydrogel technology is specifically designed for administration to the peritoneal cavity.
It can be injected as a liquid, distributes evenly in the abdomen and forms a drug depot.
UPyTher’s products are instilled as a liquid and convert to a soft, elastic gel inside the body
Route of administration fits with current clinical practices
Increases dwell time and exposure of active drugs
Technology based on supramolecular
UPy-chemistry
Spreads throughout the peritoneal cavity to all tumor sites
Improving therapeutic effects of existing drugs as intraperitoneal therapy
